Publications
5600 Results
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr 6600); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
- Year
- 2018
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1204
Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients Treated in Academic and Community Oncology Practices
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr 8015); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster discussion
- Year
- 2018
- Research Committee(s)
- Myeloma
- Study Number(s)
- S1304
Standard vs High-dose Carfilzomib (Cfz) with Dexamethasone (Dex) for Relapsed/Refractory Multiple Myeloma (RRMM): Results of S1304, An Intergroup Study
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr 9019); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster discussion, abst. 9019
- Year
- 2018
- Research Committee(s)
- Lung
- Study Number(s)
- S1400
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr 9055); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster 9055
- Year
- 2018
- Research Committee(s)
- Lung
- Study Number(s)
- S1400, S1400G
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr TPS4153); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
SWOG S1505: A Randomized Phase II Study of Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr TPS9608)ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
- Year
- 2018
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
SWOG S1512: A phase II and pilot trial of PD-1 blockade with pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM)
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr TPS9603); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
- Year
- 2018
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1607
Clinical Trial in Progress: Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716)
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr TPS3620)ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
- Year
- 2018
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1613
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr TPS9597); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
- Year
- 2018
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1616
Clinical Trial in Progress: Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)
- Journal / Conference
- J Clin Oncol 36, 2018 (suppl; abstr 1551); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
- Year
- 2018
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217